Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia

Bibliographic Details
Main Authors:	Saki Oshiro, Toru Baba, Atsushi Takeda
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	eNeurologicalSci
Subjects:	Freezing of gait Parkinson's disease Levodopa-carbidopa intestinal gel infusion therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405650221000800

Similar Items

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease
by: Melanie R. Shackleford, et al.
Published: (2022-01-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
by: Noriyuki Miyaue, et al.
Published: (2022-07-01)

Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
by: D. Santos-García, et al.
Published: (2021-03-01)

An updated calculator for determining levodopa-equivalent dose
by: D. Nyholm, et al.
Published: (2021-10-01)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
by: Peter LeWitt, et al.
Published: (2023-01-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
by: Rajesh Pahwa, et al.
Published: (2023-01-01)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
by: Daniël van Poppelen, et al.
Published: (2021-06-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

Levodopa‐Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review
by: Atsushi Imamura, et al.
Published: (2023-11-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

Utility of objective gait measures in levodopa‐unresponsive freezing in Parkinson's
by: Tuhin Virmani, et al.
Published: (2021-03-01)

A case of carbidopa/levodopa associated colitis mimicking inflammatory bowel disease
by: Michael J. Steel, et al.
Published: (2022-06-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
by: József Attila Szász, et al.
Published: (2021-06-01)

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel
by: John P. Savaryn, et al.
Published: (2024-04-01)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
by: Peter A. LeWitt, et al.
Published: (2022-11-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiao Dong Liu, et al.
Published: (2019-08-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016-01-01)

Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion
by: Gökçe Kilinçalp, et al.
Published: (2022-01-01)

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease
by: Tuhin Virmani, et al.
Published: (2023-01-01)

Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples
by: Linda Molteni, et al.
Published: (2023-05-01)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
by: K. Amande M. Pauls, et al.
Published: (2021-12-01)

Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (<i>Danio rerio</i>) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains
by: Ovidiu-Dumitru Ilie, et al.
Published: (2022-10-01)

Levodopa-Carbidopa Intestinal Gel Improves Symptoms of Orthostatic Hypotension in Patients with Parkinson’s Disease—Prospective Pilot Interventional Study
by: Simona Stanková, et al.
Published: (2022-04-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Refractory Seizures Secondary to Vitamin B6 Deficiency in Parkinson Disease: The Role of Carbidopa-Levodopa
by: Adina Wise, et al.
Published: (2022-06-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis
by: Mihaela Adriana Simu, et al.
Published: (2021-11-01)

Case series: New‐onset freezing of gait in combined use of deep brain stimulation and Levodopa
by: Mehri Salari, et al.
Published: (2021-08-01)

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
by: Noriyuki Miyaue, et al.
Published: (2023-01-01)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
by: József Attila Szász, et al.
Published: (2022-05-01)